Vanda’s Fourth Suit Against US FDA Claims Agency Shared Its Manufacturing Trade Secrets

Vanda is fighting FDA’s rejection of jet lag indication for Hetlioz as it faces generic competition for sleep-wake disorder treatment. Federal Circuit finds four Hetlioz patents invalid.

Confidential
Vanda lawsuit claims FDA shared its confidential information with competitors • Source: Shutterstock

More from US FDA

More from Agency Leadership